Varlilumab

DRUG5 trials

Sponsors

Nicholas Butowski, National Cancer Institute (NCI), University Hospital Southampton NHS Foundation Trust, Annick Desjardins, MD

Conditions

ALK-Positive Large B-Cell LymphomaAstrocytoma, Grade IIB Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic InflammationDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Phase 1

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

TerminatedNCT02924038

Nicholas ButowskiAstrocytoma, Grade II, Glioma, Glioma, Astrocytic +3

Start: 2017-04-03End: 2022-12-31Updated: 2024-06-14

A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma

CompletedNCT03307746

University Hospital Southampton NHS Foundation TrustB Cell Lymphoma

Start: 2017-11-23End: 2024-08-21Updated: 2024-12-02

Phase 2

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Active, not recruitingNCT03038672

National Cancer Institute (NCI)ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation +32

Start: 2018-12-21End: 2026-10-24Updated: 2025-11-07

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruitingNCT03688178

Annick Desjardins, MDGlioblastoma

Start: 2020-08-26End: 2026-03-31Updated: 2025-04-15

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruitingNCT04941287

National Cancer Institute (NCI)Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma +7

Start: 2021-12-15End: 2026-04-29Updated: 2025-05-23

Related Papers

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Journal of Clinical Oncology2024-06-015 citations

ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Journal of Clinical Oncology2023-01-243 citations

Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Journal of Clinical Oncology2022-06-083 citations

Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

Blood2021-11-051 citations

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Blood2019-11-135 citations

THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B‐CELL LYMPHOMAS

Hematological Oncology2019-06-01

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).

Journal of Clinical Oncology2019-05-202 citations